Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare morphologic variant of uterine corpus leiomyoma. Macroscopically, it is characterized by large, fungating, and multinodular neoplasm masses arising from the uterine corpus, and extending into the broad ligament or the peritoneal cavity. Microscopically, it shows neoplastic smooth muscle cells infiltrating the myometrium. The neoplastic cells are arranged in a micronodular pattern. Hydropic changes and increased vascularity are also present.
Biomarker and diagnostic research for uterine corpus dissecting leiomyoma has been reported in the published literature.
No clinical trials have been registered for uterine corpus dissecting leiomyoma.
125 publications have been identified in PubMed for uterine corpus dissecting leiomyoma. Research spans Review / Meta-Analysis (26%), Basic Science / Preclinical (25%), and Clinical Trial Publication (18%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 32 | 26% |
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 3:08 PM UTC
Laboratory research
31 |
25% |
Clinical study results | 23 | 18% |
Patient case studies | 21 | 17% |
Disease patterns and progression | 8 | 6% |
Testing and diagnosis research | 7 | 6% |
Other research | 2 | 2% |
New treatment approaches | 1 | 1% |
Mozaffari H (2026). [PMID: 41660920](https://pubmed.ncbi.nlm.nih.gov/41660920/). *Asian Pac J Cancer Prev*. [Epidemiology / Natural History]
Alonso-Alonso R (2026). [PMID: 42074324](https://pubmed.ncbi.nlm.nih.gov/42074324/). *Int J Mol Sci*. [Review / Meta-Analysis]
Nishibori K (2026). [PMID: 41621965](https://pubmed.ncbi.nlm.nih.gov/41621965/). *Rinsho Ketsueki*. [Clinical Trial Publication]
Armstrong AJ (2026). [PMID: 41744290](https://pubmed.ncbi.nlm.nih.gov/41744290/). *J Clin Oncol*. [Clinical Trial Publication]
Huang L (2026). [PMID: 41386109](https://pubmed.ncbi.nlm.nih.gov/41386109/). *Pathol Res Pract*. [Case Report / Case Series]
Yin Y (2026). [PMID: 40924921](https://pubmed.ncbi.nlm.nih.gov/40924921/). *Blood Adv*. [Diagnostic / Biomarker]
Likasitwatanakul P (2026). [PMID: 41782345](https://pubmed.ncbi.nlm.nih.gov/41782345/). *Oncologist*. [Basic Science / Preclinical]
Armstrong AJ (2026). [PMID: 41894648](https://pubmed.ncbi.nlm.nih.gov/41894648/). *J Clin Oncol*. [Clinical Trial Publication]
Nagar H (2026). [PMID: 40494733](https://pubmed.ncbi.nlm.nih.gov/40494733/). *Eur Urol Oncol*. [Clinical Trial Publication]
Agrusa JE (2026). [PMID: 41538304](https://pubmed.ncbi.nlm.nih.gov/41538304/). *Blood Adv*. [Basic Science / Preclinical]